What changed
Changes
Every change to a card’s legal stamp, legal line, evidence verdict, meter or red flag, every page added or retired, and every regulatory event the site records, newest first. Each build compares the site with what was last deployed; what differs is listed here, and in the feed, the moment it deploys. A status change also becomes one email. Fixes to a page’s own text are on the corrections page.
- WADA’s 2027 Prohibited List published: WADA published its 2027 Prohibited List, in force from 1 January 2027, which names SLU-PP-332 for the first time (S4.4.1, with SLU-PP-915 and related substances), adds seladelpar to S4.4.1’s PPARδ agonists, imlunestrant to S4.2, whose title now names selective estrogen receptor degraders, and eplerenone and finerenone to S5, and names peptides among S0’s examples of non-approved substances.
- ACE-031: now “Trial stopped over nosebleeds” (was “Trial halted over bleeding events”).
- Adipotide: now “Kidney injury in monkeys” (was “Kidney damage in primate trials”).
- Anamorelin: now “Life-threatening heart rhythms in case reports” (was “Heart-rhythm emergencies in case reports”).
- Methylene Blue: added: “Boxed warning: serotonin syndrome”.
- MK-677: now “Trial stopped early over heart failure” (was “Trial halted over heart failure”).
- Changes: new page.
- Argireline: now “Limited Human Data” (was “Limited Evidence”).
- BPC-157: now “Limited Human Data” (was “Preclinical”).
- BPC-157 Fragment: now “No Data” (was “Preclinical”).
- Decapeptide-12: now “Limited Human Data” (was “Limited Evidence”).
- DS5: now “No Data” (was “Preclinical”).
- GHRP-2: now “Moderate Evidence” (was “Limited Human Data”).
- Hexarelin: now “Limited Human Data” (was “Phase II”).
- Matrixyl: now “Moderate Evidence” (was “Limited Evidence”).
- Pal-AHK: now “No Data” (was “Limited Evidence”).
- Palmitoyl Dipeptide-6: now “No Data” (was “Limited Evidence”).
- Pentapeptide-18: now “Limited Human Data” (was “Limited Evidence”).
- Pinealon: now “Limited Human Data” (was “Preclinical”).
- Thymagen: now “Limited Human Data” (was “Preclinical”).
- Thymulin: now “Limited Human Data” (was “Preclinical”).
- GLP-1 & Amylin Shots: new address, /goals/glp-1-amylin-shots.html; the old one, /goals/glp-1-weight-loss-shots.html, redirects to it.
- N-Acetyl-Epithalon: now “Limited Human Data” (was “Moderate Evidence”).
- N-Acetyl Selank: now No data (was Animal only).
- N-Acetyl Semax: now No data (was Animal only).
- N-Acetyl-Epithalon: now No data (was Animal only).
- How we check: new page.
- Fat-Loss Peptides: new group page.
- GLP-1 & Weight-Loss Shots: new group page.
- All Stack Combinations: retired; its address leads to the page that does its job.
- Fat loss: split in two; its address leads to the half that kept the name.
- DSIP: now Human pilots (was Controlled trials).
- BPC-157 with Thymosin Beta-4: new combination page.
- Crystagen with Pinealon: new combination page.
- EGF with GHRP-6: new combination page.
- Stacks: new page.
- 163 combination pages: retired: a combination keeps its own page only where a published study gave the two to people together; the others open the receipt.
- BPC-157 vs TB-500 vs GHK-Cu: retired; its address leads to the receipt that replaced it.
- GHK Basic: merged into another page, where its address now leads.
- DSIP: now “Limited Human Data” (was “Moderate Evidence”).
- 3 combination pages: retired; each address opens the receipt for its pair.
- Anamorelin: new compound page.
- BAM15: new compound page.
- Cortexin: new compound page.
- CT-388: new compound page.
- Cyclic Glycine-Proline: new compound page.
- Desmopressin: new compound page.
- EGF: new compound page.
- EPO: new compound page.
- Exenatide: new compound page.
- Macimorelin: new compound page.
- PE-22-28: new compound page.
- PNC-27: new compound page.
- Prostamax: new compound page.
- Teduglutide: new compound page.
- Thymosin Beta-4: new compound page.
- Cagrilintide: now “FDA said no — its October 1, 2026 statement says it can’t be compounded” (was “No FDA ruling — not on any list”). Behind it: FDA statement on retatrutide and cagrilintide, October 1, 2026.
- Retatrutide: now “FDA said no — its October 1, 2026 statement says it can’t be compounded” (was “No FDA ruling — not on any list”). Behind it: FDA statement on retatrutide and cagrilintide, October 1, 2026.
- Abaloparatide: new compound page.
- ACE-031: new compound page.
- B7-33: new compound page.
- DNSP-11: new compound page.
- Teriparatide: new compound page.